Data as of Oct 29
| -0.16 / -1.71%|
The 6 analysts offering 12-month price forecasts for Merrimack Pharmaceuticals Inc have a median target of 14.00, with a high estimate of 16.00 and a low estimate of 11.00. The median estimate represents a +52.34% increase from the last price of 9.19.
The current consensus among 7 polled investment analysts is to Buy stock in Merrimack Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.